{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:12Z","timestamp":1790312412421,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tigecycline (TGC) is a core antibiotic for treating hospital-acquired pneumonia (HAP) caused by multidrug-resistant (MDR) bacteria, but the absence of individualized dosing guidance that balances treatment effect and safety frequently results in suboptimal efficacy or coagulation-related adverse events in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center retrospective study was conducted, enrolling 100 patients with MDR-HAP who were assigned to a standard-dose group or a high-dose group based on clinical decisions. The efficacy and safety of different TGC dosing regimens were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The trough concentration (C\n                      <jats:sub>min<\/jats:sub>\n                      ), intermediate concentration (C\n                      <jats:sub>1\/2<\/jats:sub>\n                      ), and peak concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ), the estimated ratio of the area under the concentration-time curve to the 24h of dosing\/minimum inhibitory concentration (eAUIC), pharmacokinetic\/pharmacodynamic (PK\/PD) target attainment rate, clinical response rate and overall favorable outcome rate in the high-dose group were significantly higher than those in the standard group (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). The incidence of thrombocytopenia was significantly higher in the high-dose group (36.67% vs. 17.14%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.034), whereas the incidence of hypofibrinogenemia was numerically higher but did not reach statistical significance (40.0% vs. 30.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.330). No significant between-group differences were observed in microbiological eradication rate, median survival time, 30-day all-cause mortality, coagulation parameters, gastrointestinal reactions, or liver function damage. Binary logistic regression analysis revealed that eAUIC [OR = 1.394 (1.135-1.712),\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002] was an influencing predictor associated with clinical treatment effect. The area under the receiver operating characteristic (ROC) curve for eAUIC was 0.813, with a maximum Youden index of 0.557. The corresponding critical value was determined to be 2.915, with a sensitivity of 96.9% and a specificity of 58.8%. Furthermore, eAUIC was independently associated with both hypofibrinogenemia and thrombocytopenia. We identified an exploratory candidate eAUIC range of 2.915 \u2013 3.565 that was associated with both clinical treatment effect and coagulation-related adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This eAUIC range was derived from retrospective data and should be framed explicitly as a hypothesis to be tested, clinical applicability requires confirmation through prospective studies and external validation. Therapeutic drug monitoring may assist in optimizing therapy, but prospective studies are needed to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1880928","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:10Z","timestamp":1790310490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory pharmacokinetic\/pharmacodynamic range of tigecycline for balancing treatment effect and safety in hospital-acquired pneumonia: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yating","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhua","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi International Zhuang Medicine Hospital","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boren","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi Academy of Medical Sciences and the People\u2019s Hospital of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yane","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fifth Affiliated Hospital of Guangxi Medical University and The First People\u2019s Hospital of Nanning","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob. Agents Chemotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","article-title":"Tigecycline-associated hypofibrinogenemia in a real-world setting","volume":"42","author":"Campany-Herrero","year":"2020","journal-title":"Int. Journal Clinical Pharmacy"},{"key":"B3","first-page":"964","article-title":"Expert consensus on susceptibility testing methods and reporting for polymyxins, tigecycline, and ceftazidime\/avibactam","volume":"43","year":"2020","journal-title":"Chin. J. Laboratory Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infectious Diseases An Official Publication Infect. Dis. Soc. Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infectious Diseases An Official Publication Infect. Dis. Soc. Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","article-title":"Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring","volume":"42","author":"Fan","year":"2020","journal-title":"Ther. Drug Monitoring"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e17091","DOI":"10.1097\/MD.0000000000017091","article-title":"Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"98","author":"Gong","year":"2019","journal-title":"Medicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.cmi.2016.01.001","article-title":"Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014","volume":"22","author":"Hu","year":"2016","journal-title":"Clin. Microbiology Infection The Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","article-title":"Resistance reported from China antimicrobial surveillance network (CHINET) in 2018","volume":"38","author":"Hu","year":"2019","journal-title":"Eur J Clin. Microbiol. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/antibiotics10050496","article-title":"Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients","volume":"10","author":"Kawasuji","year":"2021","journal-title":"Antibiotics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0150642","DOI":"10.1371\/journal.pone.0150642","article-title":"Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J. Antimicrobial Chemotherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107822","DOI":"10.1016\/j.ijantimicag.2026.107822","article-title":"Risk factors and serum concentration thresholds associated with tigecycline-induced hepatotoxicity in critically ill patients","volume":"67","author":"Li","year":"2026","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1159\/000532001","article-title":"Safety of tigecycline in patients on antithrombotic therapy: a single-center retrospective study","volume":"108","author":"Lin","year":"2023","journal-title":"Pharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1086\/431674","article-title":"The pharmacokinetic and pharmacodynamic profile of tigecycline","volume":"41","author":"Meagher","year":"2005","journal-title":"Clin. Infectious Diseases An Official Publication Infect. Dis. Soc. Am."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.chest.2016.04.009","article-title":"A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes","volume":"150","author":"Micek","year":"2016","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infectious Diseases"},{"key":"B18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiology Infection The Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/s0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin. Therapeutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"761167","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Pharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs","volume":"39","author":"Shen","year":"2015","journal-title":"Int. Journal Infectious Diseases IJID Official Publication Int. Soc. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4212\/cjhp.v62i5.827","article-title":"Limited-sampling strategies for anti-infective agents: systematic review","volume":"62","author":"Sprague","year":"2009","journal-title":"Can. J. Hosp. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. Aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infectious Diseases An Official Publication Infect. Dis. Soc. Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminhematol.2013.06.008","article-title":"Thrombocytopenia in the intensive care unit-diagnostic approach and management","volume":"50","author":"Thiele","year":"2013","journal-title":"Seminars Hematology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14740338.2020.1713090","article-title":"Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opinion Drug Safety"},{"key":"B26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1159\/000525380","article-title":"Tigecycline-associated coagulopathy: a single-center retrospective analysis","volume":"107","author":"Wang","year":"2022","journal-title":"Pharmacology"},{"key":"B27","first-page":"844","article-title":"Guidance for clinical trials of anti-bacterial drugs","volume":"30","year":"2014","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2013.09.008","article-title":"Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic\/pharmacodynamic analysis of tigecycline by Monte Carlo simulation","volume":"18","author":"Xie","year":"2014","journal-title":"Int. Journal Infectious Diseases IJID Official Publication Int. Soc. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00345-17","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob. Agents Chemotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijid.2019.03.011","article-title":"Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit","volume":"82","author":"Xu","year":"2019","journal-title":"Int. Journal Infectious Diseases IJID Official Publication Int. Soc. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119680","DOI":"10.1016\/j.cca.2024.119680","article-title":"Guideline for diagnosis and management of congenital dysfibrinogenemia","volume":"561","author":"Yan","year":"2024","journal-title":"Clin. Chimica Acta; International Journal Clinical Chemistry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv. Therapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-019-0300-3","article-title":"Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii","volume":"20","author":"Zhou","year":"2019","journal-title":"BMC Pharmacology and Toxicology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1880928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:11Z","timestamp":1790310491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1880928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1880928"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1880928","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1880928"}}